Typically occurring overnight, hypoglycemia puts over 8 million people with diabetes at fatal risk during their sleep. Current therapies offer hypoglycemic treatment only once an episode occurs. Zucara is working on the first treatment to prevent hypoglycemia which can kill patients in their sleep. Vancouver, Canada:  On World Diabetes Day, Zucara Therapeutics is raising awareness […]

Toronto and Vancouver, Canada: Zucara Therapeutics Inc., a diabetes life sciences company advancing the first once-daily therapeutic to prevent low blood glucose levels (hypoglycemia), has secured US$3.9 million in non-dilutive funding from The Leona M. and Harry B. Helmsley Charitable Trust. As part of the agreement, Helmsley will provide the funding to support preclinical advancement of […]

VANCOUVER and TORONTO, Canada — Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, has received support of up to $350,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP). In addition, The Centre for Drug Research and Development (CDRD) […]

Michael Midmer, CEO of Zucara Therapeutics, is confirmed to present at the 10th Annual Biotech Showcase. This important investor and networking conference is a great opportunity for Zucara to showcase our novel once-daily therapeutic to prevent hypoglycemia (low blood sugar) to life science investors and strategic partners during the industry’s most important annual gathering. More […]

NEW YORK, USA and TORONTO, Canada, September 21, 2017 — As Global Biotech Week begins in more than 20 countries, JDRF, the leading organization funding type 1 diabetes (T1D) research, is pleased to announce that it will contribute funding to Canada’s Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel therapeutic approach to […]

VANCOUVER and TORONTO, Canada — Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, is pleased to announce that Mr. Luc Mainville has been appointed Chair of its Board of Directors. Mr. Mainville is the President and Founder of LUMA Capital and LUMA […]

VANCOUVER and TORONTO, Canada (July 10, 2017) — Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, is pleased to announce that Dr. Claude Piché has joined its Board of Directors. As Co-Founder, President and CEO of Locemia Solutions, Dr. Piché led the […]

On March 3, 2017 Rocket Builders announced its 15th annual “Ready to Rocket” lists.  These lists profile British Columbia technology companies that are best positioned to capitalize on the technology sector trends that will lead them to faster growth than their peers. The annual 2017 “Ready to Rocket” lists provide accurate predictions of private companies that will […]

New paper published in The Lancet Diabetes & Endocrinology recommends exercise guidelines for type 1 diabetes patients and healthcare providers. Experts from JDRF, the leading global organization focused on type 1 diabetes (T1D) research, as part of an international team of 21 researchers and clinicians led by York University Professor Michael Riddell, published first-of-its-kind guidelines […]

For Immediate Release                                                                                     BC Ministry of Health Diabetes Awareness Month: diabetes research VICTORIA – Health Minister Terry Lake has issued the following statement for Diabetes Awareness Month: “Diabetes affects over 400,000 British Columbians of all ages. Diabetes Awareness Month is an opportunity to learn more about risk factors for this disease and the impact it has […]